This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
T. Rowe Price Investment Management filed an amendment to a Schedule 13G/A reporting beneficial ownership of 3,137,558 shares of MapLight Therapeutics common stock, representing 7.4% of the class.
The filing lists sole voting power of 8,719,082 shares and sole dispositive power of 8,741,432 shares. The filing is signed by Ellen York, Vice President, dated 05/15/2026.
MapLight Therapeutics, Inc. reported a first-quarter 2026 net loss of $60.7 million, widening from $22.3 million a year earlier, as it ramped research and development spending. R&D expenses rose to $53.7 million, driven by higher clinical trial and employee-related costs, while general and administrative expenses increased to $10.8 million.
The company ended March 31, 2026 with $395.2 million in cash, cash equivalents and investments and expects this to fund operations through 2027. MapLight remains a clinical-stage, pre-revenue biopharmaceutical company advancing Phase 2 trials for ML-007C-MA in schizophrenia and Alzheimer’s disease psychosis and ML-004 in autism spectrum disorder, with topline data from ZEPHYR and IRIS expected by mid-August 2026 and from VISTA in the second half of 2027.
MapLight Therapeutics reported first quarter 2026 results and highlighted approaching clinical milestones across its CNS portfolio. The company completed enrollment of 307 patients in the Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia and finished last patient visits in the Phase 2 IRIS trial of ML-004 in autism spectrum disorder, with topline data from both studies expected by mid-August 2026. Enrollment is ongoing in the Phase 2 VISTA trial of ML-007C-MA in Alzheimer’s disease psychosis, with topline results targeted for the second half of 2027. Cash, cash equivalents and investments were $395.2 million as of March 31, 2026, which MapLight expects will fund operations through 2027. Research and development expenses rose to $53.7 million from $19.8 million a year earlier and general and administrative expenses increased to $10.8 million from $3.8 million, driving a wider net loss of $60.7 million versus $22.3 million in the prior-year quarter.
MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported open-market sales of 13,917 shares of Voting Common Stock on May 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. The trades were executed in four tranches at weighted average prices between $27.61 and $30.56 per share.
After these transactions, Hanson directly holds 175,964 shares of MapLight Therapeutics. The filing notes that each reported price is a weighted average of multiple trades within disclosed price ranges, and Hanson has agreed to provide detailed breakdowns of individual sale prices upon request.
MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported multiple open-market sales of Voting Common Stock. Across several trades on May 7–11, 2026, he sold a total of 68,491 shares, according to the transaction summary.
The sales were executed at weighted average prices within reported ranges from about $27.11 to $30.90 per share, with detailed ranges provided for each trade. A footnote states these transactions were carried out under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre-arranged rather than timed discretionarily.
MapLight Therapeutics, Inc. Chief Medical Officer Erin Pennock Foff reported open-market sales of a total of 4,438 shares of Voting Common Stock on May 7, 2026. The trades, executed at weighted average prices around $28–$29 per share, were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff reported an open-market sale of 721 shares of Voting Common Stock on May 7, 2026 at a weighted average price of $28.28 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025, indicating it was scheduled in advance. After this transaction, Woodruff directly holds 242,729 shares of the company’s stock. The filing notes that the shares were sold in multiple trades at prices between $28.08 and $28.90 per share.
MapLight Therapeutics, Inc. Chief Financial Officer Vishwas Setia reported open-market sales of a total of 36,371 shares of Voting Common Stock over May 4–6, 2026. The trades were executed at weighted average prices reported between about $26.84 and $30.55 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025. Following these transactions, Setia directly owns 356,256 shares of MapLight Therapeutics common stock.
MapLight Therapeutics Chief Medical Officer Erin Pennock Foff sold 50,280 shares of Voting Common Stock in open-market trades. The sales occurred on May 4–6, 2026 at prices generally in the high‑$20s to low‑$30s per share.
The transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled. After these sales, Foff directly holds 350,497 shares of MapLight Therapeutics common stock.
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock in open‑market transactions. The sales occurred on May 4–6, 2026 at prices reported around the high‑$20s to low‑$30s per share, with some trades executed at weighted average prices.
After these transactions, Woodruff directly holds 243,450 shares of Voting Common Stock. The filing states that the trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled rather than discretionary market‑timed sales.